JP2014510782A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510782A5 JP2014510782A5 JP2014504431A JP2014504431A JP2014510782A5 JP 2014510782 A5 JP2014510782 A5 JP 2014510782A5 JP 2014504431 A JP2014504431 A JP 2014504431A JP 2014504431 A JP2014504431 A JP 2014504431A JP 2014510782 A5 JP2014510782 A5 JP 2014510782A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- alkyl
- compound
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000001475 halogen functional group Chemical group 0.000 claims 5
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 4
- 102000034534 Cotransporters Human genes 0.000 claims 3
- 108020003264 Cotransporters Proteins 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- 239000011734 sodium Substances 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- -1 cyano, carboxy Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161475493P | 2011-04-14 | 2011-04-14 | |
| US61/475,493 | 2011-04-14 | ||
| PCT/IB2012/051798 WO2012140596A1 (en) | 2011-04-14 | 2012-04-12 | Glycoside derivatives and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014510782A JP2014510782A (ja) | 2014-05-01 |
| JP2014510782A5 true JP2014510782A5 (enExample) | 2015-06-11 |
Family
ID=46028034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014504431A Pending JP2014510782A (ja) | 2011-04-14 | 2012-04-12 | グリコシド誘導体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8722633B2 (enExample) |
| EP (1) | EP2697240B1 (enExample) |
| JP (1) | JP2014510782A (enExample) |
| KR (1) | KR20140019834A (enExample) |
| CN (1) | CN103619862A (enExample) |
| AU (1) | AU2012241426A1 (enExample) |
| BR (1) | BR112013026361A2 (enExample) |
| CA (1) | CA2832951A1 (enExample) |
| EA (1) | EA201391524A1 (enExample) |
| MX (1) | MX2013011926A (enExample) |
| WO (1) | WO2012140596A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5876570B2 (ja) * | 2011-06-01 | 2016-03-02 | グリーン・クロス・コーポレイションＧｒｅｅｎ Ｃｒｏｓｓ Ｃｏｒｐ． | Ｓｇｌｔ２阻害剤としての新規のジフェニルメタン誘導体 |
| TR201908247T4 (tr) * | 2012-11-20 | 2019-06-21 | Lexicon Pharmaceuticals Inc | Sodyum glikoz birlikte taşıyıcı 1 inhibitörleri. |
| EP2895490B1 (en) | 2013-09-27 | 2016-10-19 | Sunshine Lake Pharma Co., Ltd. | Glucopyranosyl derivatives and their uses in medicine |
| BR122019007990B1 (pt) | 2013-11-18 | 2021-05-04 | Forma Therapeutics, Inc | Composto, e, composição farmacêutica |
| RU2720237C2 (ru) | 2013-11-18 | 2020-04-28 | Форма Терапеутикс, Инк. | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет |
| MX2018014929A (es) | 2016-06-02 | 2019-08-26 | Sanofi Sa | Conjugados de un agente farmaceutico y una porcion capaz de unirse a una proteina sensora de glucosa. |
| WO2022105845A1 (zh) * | 2020-11-19 | 2022-05-27 | 北京盈科瑞创新药物研究有限公司 | 一种糖苷类衍生物及其制备方法和应用 |
| BR112023019753A2 (pt) * | 2021-04-18 | 2023-10-31 | Ecole Polytechnique Fed Lausanne Epfl | Solventes verdes para reações químicas |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1020944C (zh) | 1990-01-30 | 1993-05-26 | 阿图尔-费希尔股份公司费希尔厂 | 紧固件 |
| EP1213296B1 (en) | 1999-08-31 | 2004-04-14 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| ES2254376T3 (es) | 2000-03-17 | 2006-06-16 | Kissei Pharmaceutical Co., Ltd. | Derivados glucopiranosiloxibencilbenceno, preparaciones medicinales que los contienen e intermediarios para la preparacion de los indicados derivados. |
| US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| JP3798375B2 (ja) | 2000-09-29 | 2006-07-19 | キッセイ薬品工業株式会社 | グルコピラノシルオキシベンジルベンゼン誘導体およびそれを含有する医薬組成物 |
| US6936590B2 (en) * | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| US20030087843A1 (en) | 2001-09-05 | 2003-05-08 | Washburn William N. | O-pyrazole glucoside SGLT2 inhibitors and method of use |
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| JP2004137245A (ja) | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| ATE510834T1 (de) * | 2003-03-14 | 2011-06-15 | Astellas Pharma Inc | C-glykosid-derivate zur behandlung von diabetes |
| AU2003902263A0 (en) | 2003-05-12 | 2003-05-29 | Fujisawa Pharmaceutical Co., Ltd. | Monosaccharide compounds |
| AR044399A1 (es) | 2003-05-20 | 2005-09-14 | Novartis Ag | Compuestos heterociclicos y su uso como activadores de receptores de ppar. composiciones farmaceuticas que los contienen |
| CN104109155A (zh) * | 2003-08-01 | 2014-10-22 | 田边三菱制药株式会社 | 新颖化合物 |
| CA2549017A1 (en) | 2003-08-01 | 2005-02-10 | Mona Patel | Substituted indazole-o-glucosides |
| CA2539032A1 (en) | 2003-08-26 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-pirazoles, drugs containing said compounds the use and production method thereof |
| CA2557320C (en) | 2004-03-04 | 2013-02-05 | Kissei Pharmaceutical Co., Ltd. | Fused heterocyclic derivatives for prevention or treatment of hyperglycemia |
| AU2005219779B2 (en) | 2004-03-04 | 2011-04-14 | Kissei Pharmaceutical Co., Ltd. | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
| US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
| DE102004034690A1 (de) | 2004-07-17 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| WO2006010557A1 (de) | 2004-07-27 | 2006-02-02 | Boehringer Ingelheim International Gmbh | D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| WO2006018150A1 (de) * | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| DE102004048388A1 (de) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| WO2006054629A1 (ja) | 2004-11-18 | 2006-05-26 | Kissei Pharmaceutical Co., Ltd. | １－置換－３－（β－Ｄ－グリコピラノシル）含窒素ヘテロ環化合物、及びそれを含有する医薬 |
| US20080027014A1 (en) | 2006-07-28 | 2008-01-31 | Tanabe Seiyaku Co., Ltd. | Novel SGLT inhibitors |
| TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
| WO2010147430A2 (en) * | 2009-06-19 | 2010-12-23 | Green Cross Corporation | Novel c-aryl glucoside sglt2 inhibitors and pharmaceutical composition comprising same |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
-
2012
- 2012-04-12 JP JP2014504431A patent/JP2014510782A/ja active Pending
- 2012-04-12 MX MX2013011926A patent/MX2013011926A/es not_active Application Discontinuation
- 2012-04-12 AU AU2012241426A patent/AU2012241426A1/en not_active Abandoned
- 2012-04-12 BR BR112013026361A patent/BR112013026361A2/pt not_active IP Right Cessation
- 2012-04-12 EA EA201391524A patent/EA201391524A1/ru unknown
- 2012-04-12 WO PCT/IB2012/051798 patent/WO2012140596A1/en not_active Ceased
- 2012-04-12 CA CA2832951A patent/CA2832951A1/en not_active Abandoned
- 2012-04-12 CN CN201280028538.2A patent/CN103619862A/zh active Pending
- 2012-04-12 US US13/634,597 patent/US8722633B2/en not_active Expired - Fee Related
- 2012-04-12 EP EP12719082.5A patent/EP2697240B1/en active Active
- 2012-04-12 KR KR1020137029814A patent/KR20140019834A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013508279A5 (enExample) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2011042668A5 (enExample) | ||
| JP2009102342A5 (enExample) | ||
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| JP2013500977A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
| JP2013518107A5 (enExample) | ||
| JP2013526544A5 (enExample) | ||
| JP2014516942A5 (enExample) | ||
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| JP2013509411A5 (enExample) | ||
| JP2019515908A5 (enExample) | ||
| JP2019529541A (ja) | 高サイトカイン血症及びウィルス感染の処置の為の肥満細胞安定剤 | |
| JP2015522033A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2012502915A5 (enExample) | ||
| JP2013518036A5 (enExample) | ||
| US20240139224A1 (en) | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist | |
| JP2020500868A5 (enExample) | ||
| JP2015516419A5 (enExample) | ||
| RU2016103098A (ru) | Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii | |
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
| JP2015524460A5 (enExample) |